Robin Jones to Clinical Trials as Topic
This is a "connection" page, showing publications Robin Jones has written about Clinical Trials as Topic.
Connection Strength
0.918
-
Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 2021; 99 Suppl 1:8-16.
Score: 0.169
-
Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates Curr Treat Options Oncol. 2020 05 27; 21(7):55.
Score: 0.159
-
Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
Score: 0.152
-
Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157.
Score: 0.131
-
Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
Score: 0.125
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
Score: 0.071
-
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7.
Score: 0.054
-
Aldoxorubicin in soft tissue sarcomas. Future Oncol. 2019 May; 15(13):1429-1435.
Score: 0.037
-
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94.
Score: 0.020